Company: REVB
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000950170-25-105284
Chunk: 5

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 5
---
 $0.1 million of personnel expenses, offset by a decrease of $0.1 million of other research and development expenses.

General and Administrative Expenses

General and administrative expenses for the three months ended June 30, 2025 and 2024 were $1.1 million for both periods.

General and administrative expenses increased by $0.1 million, from $2.3 million for the six months ended June 30, 2024 to $2.4 million for the six months ended June 30, 2025. The increase was primarily due to increases of $0.1 million in legal and professional fees.

Other (Expense) Income, Net

Other (expense) income, net was expense of $5.9 million for the three months ended June 30, 2024, primarily related to the clinical trial related settlement expenses with A-IR Clinical Research Ltd., offset by interest income from our cash balances in savings accounts. Other (expense) income, net, was minimal for the three months ended June 30, 2025.

Other (expense) income, net, was expense of $6.6 million for the six months ended June 30, 2024, primarily related to the change in fair value of the warrant liability, the clinical trial related settlement expenses with A-IR Clinical Research Ltd., foreign currency transaction gains and losses, and interest income from our cash balances in savings accounts. Other (expense) income, net,

was income of $0.06 million for the six months ended June 30, 2025, primarily related to the change in fair value of the warrant liability, foreign currency transaction gains and losses, and interest income from our cash balances in savings accounts.

Liquidity and Capital Resources

Since our inception to June 30, 2025, we have funded our operations from the issuance and sale of our common stock, preferred stock and warrants, from which we have raised net proceeds of $60.2 million. As of June 30, 2025, we had available cash and cash equivalents of $5.2 million and an accumulated deficit of $45.0 million.

Our use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to our Product Candidates. We plan to increase our research and development expenses substantially for the foreseeable future as we continue the clinical development of our current and future product candidates. At this time, due to the inherently unpredictable nature of product development, we cannot reasonably estimate the costs we will